SALARIUS PHARMACEUTICALS, INC. FLKS Cash Flow

Salarius pharmaceuticals, inc. (FLKS)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Jun'14
Operating activities
Net loss
-2,083	-1,882	-1,438	-2,093	-1,522	-1,091	16,697	-9,051	-8,223	-8,028	-9,332	-8,804	-8,268	-7,900	-10,637	-11,363	-9,592	-7,892	-8,152	-7,078	-6,017	-4,268
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and impairment
4	-	-	-	114	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation expense
-	-	-	-	-	-	-	59	64	73	79	79	91	111	75	59	30	13	16	11	9	6
Equity-based compensation expense
38	171	146	398	35	-21	-1,367	510	908	952	1,004	1,073	1,188	1,205	1,860	1,988	1,518	1,704	1,506	1,640	1,745	673
Change in fair value of warrant liability
-283	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization and accretion on investments
-	-	-	-	-	-	-	0	-12	29	22	18	-2	-	-	-	-	-	-	-	-	-
Other non-cash items
-	-	-	-	-	-	-	-25	3	-	0	0	0	-	-	-	-	-	-	-	-	-
Amortization and accretion on investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	46	-	1	0	0	0
Other non-cash items
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55
Changes in operating assets and liabilities:
Grants receivable
591	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	126
Accounts receivable
-	-	-	-	-	0	-0	4	-4	-24	0	15	6	-9	10	11	0	-	-	-	-	-
Inventory
-	-	-	-	-	0	139	-142	3	-102	286	-167	-39	344	-164	161	112	0	0	0	0	-
Prepaid expenses and other current assets
-298	-298	-66	304	-30	-34	180	-405	499	-279	-153	-376	659	-628	-705	267	1,083	-176	275	-244	684	174
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	64	-135	0	0	35	11
Accounts payable
-911	74	-1,056	-126	589	166	407	-1,096	236	1,093	-876	967	-366	-12	-186	-86	594	188	-124	246	311	279
Accrued expenses and other current liabilities
361	-84	297	-70	-462	3,245	1,156	768	-1,895	-184	1,207	377	-276	99	726	438	-517	231	330	472	536	321
Due to/from related party
0	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-541	-	-	-	-655	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-7	6	16	65	0	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-14	-14	-14	20	25	37	-6	-5	-5	7	-5	-4	-2	-6	63
Other long term liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15
Net cash used in operating activities
-3,708	-2,636	-5,501	-1,573	-1,868	387	21,457	-8,255	-9,412	-5,755	-8,051	-5,689	-8,225	-6,298	-7,252	-9,327	-9,173	-5,437	-6,703	-4,464	-4,140	-3,165
Investing activities
Purchases of marketable securities
-	-	-	-	-	-	-	0	1,997	9,622	13,757	-0	9,607	10,595	6,011	10,060	12,013	18,395	21,002	0	0	0
Proceeds from maturities and sales of marketable securities
-	-	-	-	-	-	-	2,000	14,117	14,299	3,004	23,771	16,510	11,525	2,357	4,512	8,600	1,400	10,998	0	0	0
Purchases of property and equipment
-	-	-	-	-	-	-	-	-	15	44	31	22	50	218	182	107	42	147	49	26	59
Proceeds from sales of property and equipment
-	-	-	-	-	-	-	0	0	1	0	2	0	5	0	0	0	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	0	-14,120	2,000	12,119	4,662	-10,796	23,743	6,881	884	-3,873	-5,731	-3,521	-17,037	-10,152	-49	-26	-59
Financing activities
Proceeds from issuance of equity securities, net
9,865	-	-	-	1,508	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on note payable
249	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from initial public offering, net of offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	80,435	0
Proceeds from sale of restricted common stock to founders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2
Proceeds from exercise of common stock
-	-	-	-	-	-	-	63	54	0	0	2	0	0	14	0	7	1	3	2	0	6
Proceeds from early exercise of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	400	-
Net cash provided by financing activities
9,616	2,375	1,203	-1,508	1,508	-306	1,623	63	54	0	0	2	0	0	14	0	7	1	3	2	80,835	39,517
Net increase (decrease) in cash, cash equivalents and restricted cash
5,908	-260	1,309	-3,081	-360	81	8,960	-6,191	2,762	-1,092	-18,848	18,055	-1,344	-	-	-	-	-	-	-	-	-
Net (decrease) increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11,111	-15,058	-12,687	-22,472	-16,852	-4,510	76,668	36,292
Supplemental disclosure of cash flow information:
Cash paid for interest
3	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash investing and financing activities:
Accrued issuance costs for public offering
398	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of shares for license
0	-	-	-	110	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of liabilities to equity
0	-	-	-	2,869	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IPO issuance costs paid in cash through December 31, 2014
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	575	0
Property and equipment purchases included in accounts payable at September 30, 2017
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-161	-65	226	-	5	-23	23	-
Property and equipment in accounts payable at September 30, 2015
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Property and equipment purchases included in accounts payable and accrued expenses at December 31, 2016
-	-	-	-	-	-	-	-	-	-	0	0	7	-	0	0	106	-	0	21	0	0
IPO issuance costs included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	499	43